vs

Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and Victoria's Secret & Co. (VSCO). Click either name above to swap in a different company.

Victoria's Secret & Co. is the larger business by last-quarter revenue ($1.5B vs $950.5M, roughly 1.5× Astrana Health, Inc.). Astrana Health, Inc. runs the higher net margin — 0.7% vs -2.5%, a 3.2% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 9.3%). Astrana Health, Inc. produced more free cash flow last quarter ($-6.0M vs $-232.0M). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs -15.9%).

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

Victoria's Secret is an American lingerie, clothing and beauty retailer. Founded in 1977 by Stanford graduate student Roy Raymond and his wife Gaye, the company's five lingerie stores were sold to Les Wexner in 1982. Wexner rapidly expanded into American shopping malls, expanding the company into 350 stores nationally with sales of $1 billion by the early 1990s, when Victoria's Secret became the largest lingerie retailer in the United States.

ASTH vs VSCO — Head-to-Head

Bigger by revenue
VSCO
VSCO
1.5× larger
VSCO
$1.5B
$950.5M
ASTH
Growing faster (revenue YoY)
ASTH
ASTH
+33.6% gap
ASTH
42.9%
9.3%
VSCO
Higher net margin
ASTH
ASTH
3.2% more per $
ASTH
0.7%
-2.5%
VSCO
More free cash flow
ASTH
ASTH
$226.1M more FCF
ASTH
$-6.0M
$-232.0M
VSCO
Faster 2-yr revenue CAGR
ASTH
ASTH
Annualised
ASTH
53.3%
-15.9%
VSCO

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
ASTH
ASTH
VSCO
VSCO
Revenue
$950.5M
$1.5B
Net Profit
$6.6M
$-37.0M
Gross Margin
36.4%
Operating Margin
1.9%
-1.3%
Net Margin
0.7%
-2.5%
Revenue YoY
42.9%
9.3%
Net Profit YoY
184.4%
33.9%
EPS (diluted)
$0.12
$-0.46

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTH
ASTH
VSCO
VSCO
Q4 25
$950.5M
$1.5B
Q3 25
$956.0M
$1.5B
Q2 25
$654.8M
$1.4B
Q1 25
$620.4M
$2.1B
Q4 24
$665.2M
$1.3B
Q3 24
$478.7M
$1.4B
Q2 24
$486.3M
$1.4B
Q1 24
$404.4M
$2.1B
Net Profit
ASTH
ASTH
VSCO
VSCO
Q4 25
$6.6M
$-37.0M
Q3 25
$373.0K
$16.0M
Q2 25
$9.4M
$-2.0M
Q1 25
$6.7M
$193.0M
Q4 24
$-7.8M
$-56.0M
Q3 24
$16.1M
$32.0M
Q2 24
$19.2M
$-4.0M
Q1 24
$14.8M
$180.0M
Gross Margin
ASTH
ASTH
VSCO
VSCO
Q4 25
36.4%
Q3 25
35.6%
Q2 25
35.0%
Q1 25
38.6%
Q4 24
34.7%
Q3 24
35.4%
Q2 24
36.9%
Q1 24
39.7%
Operating Margin
ASTH
ASTH
VSCO
VSCO
Q4 25
1.9%
-1.3%
Q3 25
2.0%
2.8%
Q2 25
3.1%
1.5%
Q1 25
3.3%
12.8%
Q4 24
0.1%
-3.5%
Q3 24
5.9%
4.4%
Q2 24
6.2%
1.9%
Q1 24
7.5%
12.4%
Net Margin
ASTH
ASTH
VSCO
VSCO
Q4 25
0.7%
-2.5%
Q3 25
0.0%
1.1%
Q2 25
1.4%
-0.1%
Q1 25
1.1%
9.2%
Q4 24
-1.2%
-4.2%
Q3 24
3.4%
2.3%
Q2 24
3.9%
-0.3%
Q1 24
3.7%
8.6%
EPS (diluted)
ASTH
ASTH
VSCO
VSCO
Q4 25
$0.12
$-0.46
Q3 25
$0.01
$0.20
Q2 25
$0.19
$-0.02
Q1 25
$0.14
$2.41
Q4 24
$-0.14
$-0.71
Q3 24
$0.33
$0.40
Q2 24
$0.40
$-0.05
Q1 24
$0.31
$2.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTH
ASTH
VSCO
VSCO
Cash + ST InvestmentsLiquidity on hand
$429.5M
$249.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$779.3M
$653.0M
Total Assets
$2.2B
$5.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTH
ASTH
VSCO
VSCO
Q4 25
$429.5M
$249.0M
Q3 25
$463.4M
$188.0M
Q2 25
$342.1M
$138.0M
Q1 25
$260.9M
$227.0M
Q4 24
$290.8M
$161.0M
Q3 24
$350.3M
$169.0M
Q2 24
$327.7M
$105.0M
Q1 24
$337.3M
$270.0M
Stockholders' Equity
ASTH
ASTH
VSCO
VSCO
Q4 25
$779.3M
$653.0M
Q3 25
$775.5M
$680.0M
Q2 25
$765.5M
$645.0M
Q1 25
$745.4M
$640.0M
Q4 24
$712.7M
$429.0M
Q3 24
$704.6M
$472.0M
Q2 24
$678.9M
$423.0M
Q1 24
$653.5M
$417.0M
Total Assets
ASTH
ASTH
VSCO
VSCO
Q4 25
$2.2B
$5.1B
Q3 25
$2.2B
$4.8B
Q2 25
$1.4B
$4.6B
Q1 25
$1.3B
$4.5B
Q4 24
$1.4B
$4.9B
Q3 24
$1.3B
$4.6B
Q2 24
$1.3B
$4.4B
Q1 24
$1.2B
$4.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTH
ASTH
VSCO
VSCO
Operating Cash FlowLast quarter
$-2.9M
$-180.0M
Free Cash FlowOCF − Capex
$-6.0M
$-232.0M
FCF MarginFCF / Revenue
-0.6%
-15.8%
Capex IntensityCapex / Revenue
0.3%
3.5%
Cash ConversionOCF / Net Profit
-0.44×
TTM Free Cash FlowTrailing 4 quarters
$104.5M
$309.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTH
ASTH
VSCO
VSCO
Q4 25
$-2.9M
$-180.0M
Q3 25
$10.0M
$156.0M
Q2 25
$90.9M
$-150.0M
Q1 25
$16.6M
$674.0M
Q4 24
$-10.9M
$-248.0M
Q3 24
$34.0M
$115.0M
Q2 24
$23.2M
$-116.0M
Q1 24
$6.0M
$589.0M
Free Cash Flow
ASTH
ASTH
VSCO
VSCO
Q4 25
$-6.0M
$-232.0M
Q3 25
$7.4M
$88.0M
Q2 25
$89.5M
$-193.0M
Q1 25
$13.6M
$646.0M
Q4 24
$-13.5M
$-299.0M
Q3 24
$31.7M
$55.0M
Q2 24
$20.4M
$-155.0M
Q1 24
$5.6M
$557.0M
FCF Margin
ASTH
ASTH
VSCO
VSCO
Q4 25
-0.6%
-15.8%
Q3 25
0.8%
6.0%
Q2 25
13.7%
-14.3%
Q1 25
2.2%
30.7%
Q4 24
-2.0%
-22.2%
Q3 24
6.6%
3.9%
Q2 24
4.2%
-11.4%
Q1 24
1.4%
26.7%
Capex Intensity
ASTH
ASTH
VSCO
VSCO
Q4 25
0.3%
3.5%
Q3 25
0.3%
4.7%
Q2 25
0.2%
3.2%
Q1 25
0.5%
1.3%
Q4 24
0.4%
3.8%
Q3 24
0.5%
4.2%
Q2 24
0.6%
2.9%
Q1 24
0.1%
1.5%
Cash Conversion
ASTH
ASTH
VSCO
VSCO
Q4 25
-0.44×
Q3 25
26.69×
9.75×
Q2 25
9.65×
Q1 25
2.48×
3.49×
Q4 24
Q3 24
2.11×
3.59×
Q2 24
1.21×
Q1 24
0.40×
3.27×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

VSCO
VSCO

Sales Channel North America Stores$778.0M53%
Sales Channel Directly To Consumer$429.0M29%
Sales Channel International$265.0M18%
Sales Channel Loyalty And Private Label Credit Card$19.0M1%

Related Comparisons